Co‑trimoxazole Dosing Recommendations for Dialysis Patients

Prophylaxis (e.g., PCP Prevention)

The CDC recommends giving a single‑strength tablet (80 mg trimethoprim / 400 mg sulfamethoxazole) immediately after each hemodialysis session, three times weekly, to provide effective PCP prophylaxis in dialysis patients. 1
For patients with a creatinine clearance of 15–30 mL/min who are not yet on dialysis, the CDC advises using half the standard adult dose of co‑trimoxazole for PCP prophylaxis. 2
For patients with a creatinine clearance < 15 mL/min, the CDC suggests either half‑dose prophylaxis or an alternative agent if concerns about toxicity exist. 2

The Clinical Infectious Diseases guideline states that, for active infections (e.g., urinary‑tract infection or pneumonia) in hemodialysis patients, full individual doses should be retained but the dosing interval extended (post‑dialysis dosing three times weekly) rather than reducing the dose size, because smaller doses lead to sub‑therapeutic peaks and treatment failure. 3
For severe infections such as PCP, the guideline recommends intravenous trimethoprim 3–5 mg/kg every 12 hours when creatinine clearance is 10–50 mL/min, and the same dose every 24 hours when clearance is < 10 mL/min. 3
The guideline also cautions that reducing the individual dose size instead of extending the interval results in inadequate peak concentrations and should be avoided. 3

The CDC advises initiating co‑trimoxazole in peritoneal‑dialysis patients with the same dosing used for hemodialysis (e.g., 320 mg trimethoprim / 1600 mg sulfamethoxazole every 48 hours for mild‑to‑moderate infections) and confirming adequacy through serum drug‑level monitoring because specific pharmacokinetic data are limited. 1

The CDC recommends routine serum drug‑concentration monitoring in dialysis patients receiving chronic co‑trimoxazole to ensure therapeutic exposure while avoiding excess accumulation and toxicity. 2

Both CDC and Clinical Infectious Diseases guidelines agree that co‑trimoxazole must never be administered before a dialysis session, as pre‑dialysis dosing leads to premature drug removal and therapeutic failure. 3
The recommended schedule is post‑dialysis dosing three times weekly, aligning with the drug’s clearance during dialysis and avoiding daily dosing, which is unnecessary and may increase toxicity. 3

Administer half the standard Bactrim dose (either one single‑strength tablet or ½ double‑strength tablet) immediately after each dialysis session, three times per week to maintain therapeutic levels while accounting for drug removal by dialysis. [@1]
Single‑strength tablet (400 mg SMX / 80 mg TMP) given post‑dialysis, three times weekly, is an acceptable prophylactic option. [@1]
Half a double‑strength tablet (800 mg SMX / 160 mg TMP) given post‑dialysis, three times weekly, provides equivalent prophylaxis. [@1]

For infections such as urinary‑tract infection, give one double‑strength tablet (800 mg SMX / 160 mg TMP) after each dialysis session, three times weekly. [@2]
Do not reduce the individual dose size; keep the standard per‑dose amount and extend the dosing interval to avoid sub‑therapeutic peaks and potential treatment failure. [@2]

Begin with hemodialysis‑equivalent dosing and confirm adequacy by serum drug concentration monitoring because data specific to peritoneal dialysis are limited. [@3, @4]

Serum drug concentration monitoring is recommended to ensure sufficient absorption while preventing excessive accumulation and toxicity in dialysis patients receiving TMP‑SMX. [@3, @4]
Be aware of drug interactions: TMP‑SMX can potentiate warfarin anticoagulation and may interact with antidiabetic agents and other hepatically metabolized medications. [@1]
Encourage adequate fluid intake to reduce the risk of crystalluria, although this is less of a concern in anuric dialysis patients. [@1]

Never administer TMP‑SMX before dialysis; pre‑dialysis dosing results in premature drug removal and possible treatment failure. [@1, @2]
Avoid daily dosing in hemodialysis patients; the three‑times‑weekly post‑dialysis schedule aligns with the drug’s clearance pattern during dialysis. [@1, @2]
Do not rely on standard renal dosing charts for dialysis patients; dialysis‑specific guidelines supersede non‑dialysis chronic‑kidney‑disease dosing recommendations. [@2]